Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- CPB +3.1%
Other news:
- VERA +74.6% (announced that the primary endpoint was met in the ORIGIN Phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy (IgAN) in adults)
- BPMC +27% (Blueprint Medicines to be acquired by Sanofi for $129.00 per share)
- BNTX +13.3% (BioNTech and Bristol Myers Squibb (BMY) to co-development and co-commercialization BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types)
- KYMR +13% (clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine)
- ATAI +12.6% (atai Life Sciences N.V. and Beckley Psytech to combine to create leader in psychedelic mental health therapies)
- TRVI +11.7% (Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough)
- TBPH +11.1% (divests remaining royalty interest in Trelegy Ellipta to GSK for $225 million)
- IMTX +8.5% (IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma)
- LQDA +7.8% (announced that Liquidia is scheduled to make its first commercial shipment of YUTREPIA inhalation powder)
- CANG +5.5% (definitive agreement with Founders and EWCL)
- TVRD +5% (files for 2,084,117 share common stock offering by selling shareholders)
- TLSI +5% (files for 5.5 mln share common stock offering by selling shareholders)
- KURA +4.4% (Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML)
- MRNA +4.1% (receives FDA approval for COVID-19 Vaccine mNEXSPIKE )
- ZLAB +3.7% (Zai Lab and Novocure (NVCR) Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting; Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting)
- RCUS +3% (Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response)
- PONY +2.5% (forms strategic partnership with Xihu Group for Robotaxi deployment in Shenzhen)
- ASPI +1.9% (ASP Isotopes and Isotopia announce supply agreement for Gadolinium-160 to accelerate Terbium-161 production for advanced cancer therapies)
- FLNG +1.8% (finalizes $175 million lease financing for Flex Courageous)
- ALLO +1.7% (Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO )
- CVE +1.5% (provides operations update on impact of Alberta wildfires)
- GSK +1.4% (Linerixibat file accepted for review by FDA)
- NIO +1.1% (May deliveries)